See every side of every news story
Published loading...Updated

MDA 2025: High-dose Spinraza appears safe, effective in DEVOTE study

Summary by SMA News Today
A higher dose of Spinraza (nusinersen) may be more effective than the currently approved dosing schedule in people with spinal muscular atrophy (SMA) for maintaining motor function, according to data from the DEVOTE clinical trial. Results from the study, which was sponsored by Spinraza’s maker Biogen, were presented at the annual meeting of the Muscular Dystrophy Association (MDA) in the poster, “Exploring higher doses of nusinersen in spinal m…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

SMA News Today broke the news in on Monday, March 24, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.